Hepatitis A Vaccinations Highly Recommended
If you are a Hepatitis C patient and have not yet been vaccinated against Hepatitis A, you should be as... View Article
Continue reading »Research & Treatment News
Share
Follow Us
TLR7 Agonist against HCV
Wow. Another promising candidate for more effective (and less toxic) HCV treatment. We’ll keep you posted on this one, as... View Article
Continue reading »Vertex Advances on VX-950
Vertex has really been getting a positive roll on its clinical studies for VX-950 so far. It may be the first of a new generation of Hepatitis c therapies to hit the market, and that has investors very excited. Not to mention patients.
Continue reading »Phase 1 Clinical Trial In Offing
Yet another treatment in the pipeline. But, this one is at the very beginning stages. They are still trying to discover whether it is even safe (let alone effective). Stay tuned...
Continue reading »Study Enrollment is Announced
Aug 13, 2005
1 Comment
This is a drug being developed in Canada in cooperation with Schering Plough. Seeing as Schering is currently the number... View Article
Continue reading »A Drug Treatment Based on Glutathione
Aug 11, 2005
2 Comments
Okay. This story is of most interest to me because of the origin of the compound they are studying. Oxidized... View Article
Continue reading »Tarvacin Studied for HCV
Aug 10, 2005
1 Comment
This is an unusual post for us. First we have the official press release on a new approach to HCV and then the comments from an interested observer. We think you will find this information to be of great interest.
Continue reading »Another HCV Treatment Advance
Aug 7, 2005
3 Comments
Here is another report of progress being made with a unique approach to treatment of the Hepatitis c virus. With so many companies working on a treatment, the odds are on our side that one will be proven and approved in the next 5 years or so.
Continue reading »HCV Treatment and Obesity
Aug 4, 2005
1 Comment
This article contains quite a few tidbits of good information (in addition to the primary focus). The description of "signs" that a small number of patients have does a good job of covering possible symptoms and effects of the disease. It also seems that the main difference in success between Pegasys and Peg-Intron in these patients may have more to do with the difference in dosing between standard levels of medication and weight based dosing.
Continue reading »HCV Fighters
This is an article from Forbes. Again, the business side of this disease can provide quite a bit of information for us patients. The fact that Credit Suisse First Boston likes VX-950 is certainly a good sign.
Continue reading »
